Rob Fannon: “Two Best Medical Stocks of 2008”

By Travis Johnson, Stock Gumshoe, February 18, 2008

I’m catching up from a long weekend away, so I’m sharing an unedited submission from one of my readers — if you were away over the weekend and missed the new posts, here are the links for you:

Ian Cooper’s secret release of Monday night that could double or triple after March results.

… and …

Carla Pasternak’s high yield teaser investment for this month.

And new today, we’ve got another submission from Streetsifter, a longtime reader and supporter who has sent in a few writeups for us. He even writes as the Gumshoe to save me the effort of editing up his work, which I love, but you can tell it’s him because he usually throws in a few extra prods to donate to your friendly neighborhood Stock Gumshoe. I’ll be catching up on my email and seeing if there are some exciting new ideas to share with you later in the week, but for now I’m quite grateful to Streetsifter for giving me something to share with you today … I haven’t actually read this one or checked the facts, but he has always been dead-on right before. He also threw this out for review in the Stock Gumshoe Forum in case you’d like to toss your two cents on the pile (or you can always comment right here, of course).

So without further ado, for those looking for something new, a few picks sleuthed out by Streetsifter, in his words:

Stansberry and Associates is circulating yet another teaser for Rob Fannon’s Phase I Investor newsletter, which normally focuses on medical and biotech stocks, and at a subscription rate of $5,000 per year, is their most expensive newsletter. However, for a mere $1,000 you can subscribe for a three month trial run and gain access to Fannon’s special “Double Your Money in Three Years” report with the details on “two backdoor plays to the cosmetic boom”. Or you can keep reading this post and see the likely solutions to the teaser, save the $1,000, and perhaps use a small portion of the savings to help maintain this site by joining the Stock Gumshoe Irregulars.

But hey, you’re interested in solutions, not my efforts to pay the rent. So what clues does this teaser provide regarding these two cosmetic firms?

Company #1

* Has no debt on their balance sheet
* Had “record breaking profits in 2007, with highest ever quarterly sales and year-over-year growth of 60%
* “In Feb. 2007, this small equipment supplier entered into a 10-year exclusive collaboration to commercialize home-use light-based devices for treatments of wrinkles, age and sun spots, cellulite, acne and hair removal.”

Company # 2

* “offers a laser-based alternative to the traditionally invasive liposuction procedure” The device is FDA approved and has been featured on EI, Access Hollywood, and Montel Williams.
* Had revenue growth of 70% in 2007
* “offers five main cosmetic systems primarily used for anti-aging procedures, vascular lesions, hair removal and cellulite reduction”

Using these clues, the Gumshoe’s trusty Thinkolator feeds us the results in reverse order, ranked by the level of confidence in the solution.

So Company #2 with the liposuction device is:

Cynosure (CYNO: NASDAQ)

The Food and Drug Administration approved Cynosure’s Smartlipo ™ device in October 2006. Their 70% revenue growth was recorded in the third quarter of 2007, and can be confirmed at in this corporate news release. And the five main cosmetic systems include Accolade™, Affirm™, Cynergy™, Elite™, and Smartlipo™.

The results for Company #1 satisfy most, but not all, of the clue criteria. So our qualified candidate for the solution is

Syneron Medical Ltd (ELOS: NASDAQ)

Syneron, based in Israel, reported in a February 12, 2008 press release, “Revenues for the fourth quarter of 2007 grew to an all-time quarterly high of $38.1 million”. The same press release